National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.
School of Psychological Sciences, University of Tasmania, Hobart, Australia.
Addiction. 2022 Jan;117(1):182-194. doi: 10.1111/add.15620. Epub 2021 Jul 16.
To describe (i) self-reported changes in drug use and (ii) trends in price, perceived availability, and perceived purity of illicit drugs, among people who regularly use ecstasy/ 3,4-methylenedioxymethamphetamine (MDMA) and other illicit stimulants in Australia following COVID-19 and associated restrictions.
Annual interviews with cross-sectional sentinel samples conducted face-to-face in 2016-19 and via video conferencing or telephone in 2020. Data were collected via an interviewer-administered structured questionnaire.
Australian capital cities.
Australians aged 16 years or older who used ecstasy/MDMA and other illicit stimulants on a monthly or more frequent basis and resided in a capital city, recruited via social media and word-of-mouth (n ~ 800 each year).
Key outcome measures were self-reported illicit drug market indicators (price, purity and availability) and, in 2020 only, perceived change in drug use (including alcohol and tobacco) since March 2020 and reasons for this change.
For most drugs, participants reported either no change or a reduction in their use since COVID-19 restrictions were introduced. Ecstasy/MDMA was the drug most frequently cited as reduced in use (n = 552, 70% of those reporting recent use), mainly due to reduced opportunities for socialization. While market indicators were largely stable across most drugs, the odds of perceiving MDMA capsules as 'high' in purity decreased compared with 2016-19 [adjusted odds ratio (aOR) = 0.72, 95% confidence interval (CI) = 0.53-0.99], as did perceiving them as 'easy' to obtain (aOR = 0.42, CI = 0.26-0.67). The odds of perceiving cocaine and methamphetamine crystal as 'easy' to obtain also decreased (aOR = 0.67, CI = 0.46-0.96 and aOR = 0.12, CI = 0.04-0.41, respectively).
After COVID-19-related restrictions were introduced in Australia, use of ecstasy/MDMA, related stimulants and other licit and illicit drugs mainly appeared to remain stable or decrease, primarily due to impediments to socialization.
描述(i)在澳大利亚,经常使用摇头丸/ 3,4-亚甲基二氧甲基苯丙胺(MDMA)和其他非法兴奋剂的人群中,自 COVID-19 及其相关限制以来,药物使用情况的自我报告变化,以及(ii)非法毒品的价格、可及性和纯度的趋势。
2016-19 年面对面进行年度访谈,并在 2020 年通过视频会议或电话进行。数据通过访谈者管理的结构化问卷收集。
澳大利亚首都城市。
年龄在 16 岁或以上,每月或更频繁地使用摇头丸/MDMA 和其他非法兴奋剂,并居住在首都城市的澳大利亚人,通过社交媒体和口碑招募(每年约 800 人)。
主要结局指标是自我报告的非法毒品市场指标(价格、纯度和可及性),以及仅在 2020 年报告自 2020 年 3 月以来药物使用情况(包括酒精和烟草)的变化及其变化的原因。
对于大多数药物,参与者报告说,自 COVID-19 限制措施实施以来,他们的使用量要么没有变化,要么减少。摇头丸/MDMA 是报告最近使用量减少的最常见药物(n=552,占报告最近使用量的 70%),主要是因为社交机会减少。尽管大多数药物的市场指标基本保持稳定,但与 2016-19 年相比,认为 MDMA 胶囊纯度“高”的几率降低(调整后的优势比[aOR] = 0.72,95%置信区间[CI] = 0.53-0.99),认为它们“容易”获得的几率也降低(aOR = 0.42,CI = 0.26-0.67)。可卡因和冰毒晶体“容易”获得的几率也降低(aOR = 0.67,CI = 0.46-0.96 和 aOR = 0.12,CI = 0.04-0.41,分别)。
在澳大利亚实施与 COVID-19 相关的限制措施后,摇头丸/MDMA、相关兴奋剂以及其他合法和非法药物的使用主要似乎保持稳定或减少,主要是由于社交障碍。